EFL 192 Pill - white round
Generic Name: eflornithine
Pill with imprint EFL 192 is White, Round and has been identified as Iwilfin 192 mg. It is supplied by US WorldMeds, LLC.
Iwilfin is used in the treatment of Neuroblastoma and belongs to the drug class miscellaneous antineoplastics. Iwilfin 192 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for EFL 192
Iwilfin
- Generic Name
- eflornithine
- Imprint
- EFL 192
- Strength
- 192 mg
- Color
- White
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Miscellaneous antineoplastics
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- US WorldMeds, LLC
- National Drug Code (NDC)
- 78670-0150
See also:
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Platinol
Platinol is used for bladder cancer, blood cell transplantation, bone marrow transplantation, brain ...
Oncovin
Oncovin is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Danyelza
Danyelza (naxitamab-gqgk) is a GD2-binding monoclonal antibody used for the treatment of patients ...
Vincristine
Vincristine is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Cyclophosphamide
Cyclophosphamide is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, brain ...
More about Iwilfin (eflornithine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.